Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telmisartan versus candesartan or usual therapy for brown fat activity in adults with uncomplicated hypertension
ACTRN12614000610639Phase 2Recruiting
- Sponsor
- Garvan Institute of Medical Research
- Start
- Jul 2014
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of telmisartan and candesartan in hypertension (HTN) (3 arms), sponsored by Garvan Institute of Medical Research. Primary endpoint: Brown fat abundance and activity. Started Jul 2014; status: recruiting.
02
Drugs
telmisartancandesartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ACTRN12614000610639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000610639.